Morgan Stanley’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-60
| Closed | -$5 | – | 8003 |
|
|
2022
Q4 | $5 | Buy |
60
+59
| +5,900% | +$7 | ﹤0.01% | 7834 |
|
|
2022
Q3 | $0 | Sell |
1
-3
| -75% | -$1 | ﹤0.01% | 8065 |
|
|
2022
Q2 | $0 | Sell |
4
-5,996
| -100% | -$1.55K | ﹤0.01% | 8164 |
|
|
2022
Q1 | $2K | Sell |
6,000
-10
| -0.2% | -$11 | ﹤0.01% | 7798 |
|
|
2021
Q4 | $14K | Buy |
6,010
+10
| +0.2% | +$30 | ﹤0.01% | 7361 |
|
|
2021
Q3 | $14K | Sell |
6,000
-500
| -8% | -$1.9K | ﹤0.01% | 7230 |
|
|
2021
Q2 | $36K | Sell |
6,500
-210,790
| -97% | -$1.13M | ﹤0.01% | 6801 |
|
|
2021
Q1 | $1.14M | Buy |
217,290
+211,290
| +3,522% | +$1.16M | ﹤0.01% | 4633 |
|
|
2020
Q4 | $21K | Sell |
6,000
-147
| -2% | -$419 | ﹤0.01% | 6428 |
|
|
2020
Q3 | $12K | Buy |
6,147
+6,047
| +6,047% | +$13.9K | ﹤0.01% | 6225 |
|
|
2020
Q2 | $0 | Hold |
100
| – | – | ﹤0.01% | 6794 |
|
|
2020
Q1 | $0 | Buy |
+100
| New | +$204 | ﹤0.01% | 6797 |
|
|
2018
Q1 | – | Sell |
-50
| Closed | – | – | 6751 |
|
|
2017
Q4 | $0 | Hold |
50
| – | – | ﹤0.01% | 6702 |
|
|
2017
Q3 | $0 | Hold |
50
| – | – | ﹤0.01% | 6656 |
|
|
2017
Q2 | $0 | Hold |
50
| – | – | ﹤0.01% | 6685 |
|
|
2017
Q1 | $0 | Sell |
50
-1,000
| -95% | -$1.66K | ﹤0.01% | 6642 |
|
|
2016
Q4 | $1K | Sell |
1,050
-200
| -16% | -$316 | ﹤0.01% | 6474 |
|
|
2016
Q3 | $2K | Sell |
1,250
-5
| -0.4% | -$11 | ﹤0.01% | 6383 |
|
|
2016
Q2 | $4K | Buy |
1,255
+981
| +358% | +$2.3K | ﹤0.01% | 6270 |
|
|
2016
Q1 | $1K | Hold |
274
| – | – | ﹤0.01% | 6496 |
|
|
2015
Q4 | $1K | Sell |
274
-10,169
| -97% | -$41K | ﹤0.01% | 6587 |
|
|
2015
Q3 | $45K | Sell |
10,443
-4,330
| -29% | -$17.6K | ﹤0.01% | 5776 |
|
|
2015
Q2 | $64K | Buy |
14,773
+14,318
| +3,147% | +$43.1K | ﹤0.01% | 5770 |
|
|
2015
Q1 | $2K | Sell |
455
-25
| -5% | -$103 | ﹤0.01% | 6441 |
|
|
2014
Q4 | $3K | Hold |
480
| – | – | ﹤0.01% | 6409 |
|
|
2014
Q3 | $4K | Sell |
480
-192
| -29% | -$1.76K | ﹤0.01% | 6373 |
|
|
2014
Q2 | $6K | Buy |
672
+50
| +8% | +$584 | ﹤0.01% | 6267 |
|
|
2014
Q1 | $8K | Sell |
622
-156
| -20% | -$2.54K | ﹤0.01% | 6172 |
|
|
2013
Q4 | $18K | Sell |
778
-406
| -34% | -$11K | ﹤0.01% | 5900 |
|
|
2013
Q3 | $37K | Hold |
1,184
| – | – | ﹤0.01% | 5231 |
|
|
2013
Q2 | $37K | Buy |
+1,184
| New | +$40.8K | ﹤0.01% | 5228 |
|
Other funds holding STAB
Morgan Stanley's STAB Position: Q1 2023 in Review
Morgan Stanley sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q1 2023, closing a stake of 60 shares — an estimated $5 sold.
Morgan Stanley first reported a position in STAB in Q2 2013 and held it in 31 quarters. The position peaked at $1.14M in Q1 2021. 4 funds tracked by Wall St. Rank hold STAB as of Q1 2023.
- Morgan Stanley reported no remaining Statera Biopharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
- Morgan Stanley sold 60 Statera Biopharma, Inc. Common Stock shares in Q1 2023, an estimated $5.
- Morgan Stanley first reported a position in Statera Biopharma, Inc. Common Stock in Q2 2013 and held it in 31 quarters.
- Morgan Stanley's Statera Biopharma, Inc. Common Stock position peaked at $1.14M in Q1 2021.
- 4 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q1 2023.
Based on Morgan Stanley's 13F filing for Q1 2023, filed 15 May 2023.